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Abstract: Background: Previous studies have demonstrated elevated levels of excitatory amino acids (EAA) glu-
tamate (Glu) and aspartate (Asp) in the synovial fluid (SF) of patients with active arthritis. The source of SF EAA 
concentrations are thought in large part to be secondary to passive diffusion from the plasma across synovial mem-
branes and less so, reflective of local synovial pathology. Objective: This descriptive report assesses the hypothesis 
that the SF EAA levels reflect inflammatory processes of the joint and are not dependent on plasma levels. Methods: 
Simultaneously drawn plasma and SF samples were obtained from 14 recently deceased cadavers and 10 patients 
with active arthritis. Plasma and SF EAA and other amino acid (AA) levels were determined by HPLC. SF: Plasma 
compartment concentration ratios were calculated to assess if SF EAA levels were similar to plasma levels. Results: 
In the cadavers with no antemortem arthritis, the mean SF: Plasma ratios for Glu and Asp were 4-5-fold lower than 
the mean ratios seen for 9 other AAs, showing specific discrepancies of EAA levels between plasma and synovial 
fluid. In 9 patients with active arthritis, the SF: Plasma concentration ratios were higher in samples derived from 
inflammatory arthropathies. Conclusions: Clinical samples demonstrated distinct, independent compartmental EAA 
concentrations between blood and joint compartments in support that local arthritic processes rather than plasma 
influence SF EAA concentrations. The SF EAA levels, whether from local cell production, local neurogenic sources, 
and/or transport-gradient mechanisms, parallel local pathology in the joint compartment and thus serve as sur-
rogate biomarkers of local inflammatory processes.
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Introduction
Previous studies have demonstrated elevated 
levels of excitatory amino acids (EAA) and other 
neurotransmitters in synovial fluid (SF) extract-
ed from patients with active arthritic conditions 
[1-3] [McNearney TA, Goel N, Lisse JL, Speegle 
D, Cao S and Westlund KN. Neurotransmitter 
excitatory amino acids in synovial fluids demon-
strate distinct temporal fluctuations in active 
arthritis, submitted]. Additional studies have 
reported elevated plasma amino acid (AA) lev-
els in patients with rheumatoid arthritis com-
pared to normal controls [4]. The source(s) of 
increased SF EAA levels is not known but pos-
sibilities include local cell production, neuro-
genic exudation, or passive diffusion from the 
blood or plasma across synovial membranes. 
The concentration elevations of SF EAA in 
symptomatic arthropathies and their reported 
association with SF RANTES, and MIP1-alpha 
concentrations promotes the hypothesis that 
local inflammatory joint processes rather than 
passive diffusion from plasma determines SF 
EAA concentrations [5]. To assess this, simulta-
neously drawn plasma and synovial fluids from 
the knees of 14 recently deceased cadavers 
and 9 patients with active arthritis were 
obtained and measured for EAA and other AA 
levels to assess the compartmental SF: Plasma 
concentration ratios. Disparate ratios between 
these compartments would support the con-
cept that EAA and other AA levels are primarily 
determined by local inflammatory arthritic pro-
EAA compartmental differences reflect arthritis
493 Int J Clin Exp Pathol 2013;6(3):492-497




All clinical samples collected and medical 
record reviews were under approved protocols 
by the University of Texas Medical Branch 
Institutional Review Board (IRB) with appropri-
ately authorized informed consent.
Cadavers
Autopsy specimens were considered accept-
able for study if samples were harvested within 
24 hours after witnessed death. Written con-
sent was obtained from the family or authorized 
persons for fluid harvest, medical record review, 
and physical examination before plasma and 
synovial fluids were harvested, per IRB proto-
col. Cadaveric samples (N=14) were available 
for which there was no clinical or antemortem 
history of active arthritis at the time of death. 
Blood was obtained by venipuncture or cardiac 
puncture, as routinely obtained for autopsy 
cases in tubes with EDTA. Synovial fluids were 
obtained by introduction of a 16-gauge needle 
below the patella and aspiration of the joint 
fluid. In nonedematous or nonarthritic condi-
tions, the synovial fluid harvest was usually 
between 0.5-2.0 ml of viscous, clear, or pale 
yellow fluid. In patients with peripheral (general-
ized) edema or antemortem arthritic condi-
tions, it was possible to harvest larger volumes 
(5-8 ml) of fluid from the knee joints.
Patients
After written consent was obtained, SF from 
the active arthritic knee was obtained at the 
time of diagnostic or therapeutic arthrocente-
sis. Venipuncture was performed simultane-
ously. Sample processing has been previously 
described [3]. The arthritic conditions were 
diagnosed by faculty members of the University 
Rheumatology division based on diagnostic cri-
teria [6]. These included: rheumatoid arthritis, 
acute gout, acute Reiters syndrome, osteoar-
thritis, pseudogout and sympathetic effusion in 
a patient with catastrophic antiphospholipid 
antibody syndrome (APAS).
High pressure liquid chromatography (HPLC), 
experimental standards and quality control
The protocols, standards and internal controls 
for HPLC determination have been previously 
described [3].
Figure 1. A: SF: Plasma ratios of 12 amino acid concentrations (µM) determined by HPLC derived from 14 cadav-
ers. SF: Plasma ratios are shown as mean values +/- standard error. EAA: glutamate (Glu); aspartate (Asp) and 
glutamine (Gln). Other amino acids include serine (Ser); glycine (Gly); arginine (Arg); citrulline (Ctn); threonine (Thr); 
alanine (Ala); tyrosine (Tyr); taurine (Tau) and asparagine (Asn). *: p<0.01 comparing the mean Glu SF: Plasma ratio 
to non EAA amino acids. **: p<0.01 comparing the mean Asp SF: Plasma ratio to non EAA amino acids. These data 
support compartmental differences for EAA relative to other AA. B: SF: Plasma ratios of amino acid concentrations 
(µM) of plasma and knee SF determined by HPLC derived from a patient with active Reiter’s syndrome. SF: Plasma 
ratios are shown as mean values +/- standard error. In a patient with active inflammatory synovitis, the mean SF: 
Plasma ratios for EAA were much higher compared to the ratios of other amino acids. *: p<0.01 comparing the 
mean Glu SF: Plasma ratio to non EAA amino acids. **: p<0.01 comparing the mean Asp SF: Plasma ratio to non 
EAA amino acids.
EAA compartmental differences reflect arthritis
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Quantities (in μM) from HPLC are presented as 
the mean SF: Plasma EAA concentration ratios 
or mean SF: Plasma AA concentration ratios. 
The neurotransmitter EAA’s measured were 
glutamate (Glu) and aspartate (Asp). Other AAs 
measured included serine (Ser) and glycine 
(Gly), as neurotransmitter inhibitory amino 
acids (IAA) and AA used as metabolic controls: 
glutamine (Gln), arginine (Arg), threonine (Thr), 
alanine (Ala), taurine (Tau), tyrosine (Tyr) and 
asparagine (Asn).
Statistics
Each sample had three determinations. Data 
are presented as average values +/- SE. 
Analyses of concentrations were determined by 
Mann-Whitney U tests. A p value <0.05 was 
considered significant. Average SF: Plasma 
concentration ratios were also determined and 
plotted with positive values showing higher val-
ues in the joint and negative values showing 
higher values in the plasma (blood).
Results
Mean SF: plasma EAA concentration ratios 
demonstrate significant compartmental dis-
parity
Figure 1A depicts the mean SF: Plasma con-
centration ratios of the EAA and other AA from 
14 cadavers without evidence of active ante-
mortem arthritis. The mean SF: Plasma con-
centration ratios for 14 cadaveric samples 
were <1 for all EAA and other AA, However, the 
mean SF: Plasma concentration ratio disparity 
for Glu was much greater compared to the 
other AA (Glu: -22.15-fold, p<0.01 compared to 
all other AA except Asp). The mean Asp SF: 
Plasma concentration ratios were much great-
er for other AA except for Tau, (Asp: -17.16-fold 
p<0.01 all non EAA except Tau; Asp vs. Tau p= 
0.059). The mean SF: Plasma concentration 
ratios of other AA’s were much less disparate 
and are as follows: Gln: -1.61; Ser: -3.96; Gly: 
-2.11; Arg: -0.68; Ctn: -2.13; Thr: -1.92; Ala: 
-2.69; Tau: -1.57; Tyr: -5.71 and Asn: -1.93. 
Nonarthritic cadaver SF Glu and Asp levels 
were in close agreement with previously report-
ed baseline levels [3]. For all cadavers with no 
antemortem arthritis, mean SF Glu concentra-
tions ranged from 0.28 - 26.26 µM and mean 
Asp concentrations ranged from 0 - 11.93 μM. 
From the plasma samples, mean plasma Glu 
concentrations ranged from 9.48 - 80.50 µM 
and mean plasma Asp concentration ranged 
from 0 - 73.36 µM among the cadavers.
Figure 1B depicts the mean EAA and other AA 
SF: Plasma concentration ratios from samples 
derived from a patient with acute Reiter’s syn-
drome. The mean SF: Plasma concentration 
ratio for Glu: 7.50±0.18-fold, p<0.01 compared 
to all AA except Asp. The mean Asp SF: Plasma 
concentration ratios for Asp: 4.49±0.39-fold 
p<0.01, compared to other AA except Glu. The 
samples from the patient with acute Reiter’s 
syndrome with symptomatic synovitis demon-
strates that higher SF EAA concentrations 
reflect the intense inflammatory pathology of 
the joint compartment relative to the plasma 
concentrations (blood compartment) in this 
systemic illness.
Figure 2 demonstrates mean SF: Plasma EAA 
concentration ratios of 9 patients with active 
arthritis or synovial effusion who underwent 
simultaneous blood draws and arthrocenteses. 
Patient 1 had Reiter’s syndrome (RS); patients 
2 and 3 had rheumatoid arthritis (RA); patients 
4 and 5 had acute gout; patients 6 and 7 had 
osteoarthritis; patient 8 had pseudogout (PG) 
and patient 9 had a sympathetic synovial effu-
sion from complications of antiphospholipid 
antibody syndrome (APAS). Patients 1-5 gener-
ally had mean SF: Plasma EAA concentration 
ratios >1, reflecting higher SF EAA concentra-
tions in the joint compartment. Patients 6-9 
had arthritic conditions with mean SF: Plasma 
ratios <1, reflecting lower inflammatory arthritic 
activity. relative to any systemic processes. 
Patients 8 and 9 had severe systemic illnesses 
(acute bacterial pneumonia and catastrophic 
APAS, respectively) which resulted in signifi-
cantly higher concentrations of plasma EAA 
and other AA. Thus, these patients had lower 
mean SF: Plasma ratios (<1), as inordinately 
higher plasma EAA levels reflected severe sys-
temic illnesses. To serve as templates, the far 
right of the graph depicts SF: Plasma concen-
tration ratios from cadaveric samples from a RA 
patient who had active synovitis at the time 
death (+) and from a patient who had no ante-
mortem history of active arthritis (-). Table 1 is 
a summary of the pertinent clinical laboratory 
results of the nine patients from whom the 
samples were derived, including the SF WBC 
counts, which serve as inflammatory indices for 
synovial effusions. Table 1 also demonstrates 
EAA compartmental differences reflect arthritis
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that blood WBC counts or SF white cell counts 
alone do not account for the SF or plasma EAA 
concentrations or the SF: Plasma EAA concen-
tration ratios.
Discussion
This descriptive study is the first to assess the 
relative compartmental concentrations of 
amino acids between plasma and synovial fluid 
and indicates a clinical compartmental rele-
vance to increased SF Glu and Asp concentra-
the mean plasma concentrations of cadavers 
with no active antemortem infectious or inflam-
matory conditions are in close agreement to 
the plasma levels obtained from 15 normal 
healthy controls (Data not shown). Moreover, 
SF samples with no antemortem arthritis are in 
close agreement to baseline levels obtained in 
healthy rats (Data not shown).
The SF: Plasma EAA ratio discrepancies might 
also reflect the necessity of energy dependent 
glutamate transporter proteins in peripheral 
Table 1. Summary of patient diagnoses, age and cell counts
Patient # 1 2 3 4 5 6 7 8 9
Diagnosis RS RA RA Gout Gout OA OA PG APAS
Age, yrs 37 73 29 63 67 54 41 79 27
Pl WBC # 10 8.0 6.9 13.6 6.5 NA 8.6 8.1 6.3
SF WBC # 44.0 6.0 31.0 19.2 31.0 NA 280 0.33 0.123
SF Lym # 3.15 0.24 1.5 NA 0.3 NA 002 0.04 0.006
Intracell. Crystals --- --- --- ++ UA ++ UA --- --- ++ CPPD ---
Diagnosis: RS: Reiters syndrome, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus; OA: osteoarthritis, PG: pseudo-
gout, APAS: antiphospholipid antibody syndrome; Age: in years; Pl WBC #: plasma white blood cell count, /mm3x1000; SF WBC 
#: synovial fluid white blood cell count /mm3x1000; SF Lym. #: synovial fluid lymphocyte count/mm3x1000. Intracell. Crystals: 
intracellular crystals in SF, UA: uric acid crystals, CPPD: intracellular calcium pyrophosphate dihydrate; ND: not done.
Figure 2. SF: Plasma ratios of amino acid concentrations (µM) 
of plasma and knee SF determined by HPLC derived from pa-
tients with active arthritis. SF: Plasma ratios are shown as 
mean values +/- standard error. The lanes depict patients with, 
1: Reiter’s syndrome (RS); 2 and 3: rheumatoid arthritis (RA); 4 
and 5: acute gout; 6 and 7: osteoarthritis (OA); 8: pseudogout 
(PG) and 9: sympathetic effusion in a patient with antiphos-
pholipid antibody syndrome (APAS). The values above the x-
axis are conditions where the EAA concentrations are higher in 
the joint fluid compared to blood. The values below the x-axis 
represent conditions where the plasma EAA values are higher 
than the SF levels. Closed bars depict glutamate (Glu); open 
bars depict aspartate (Asp).
tions in patients with active arthritis. The 
sources of elevated SF Glu and Asp con-
centrations in active arthritis are unknown, 
but likely candidates include plasma, local 
production from synoviocytes or osteo-
cytes in the joint capsule or local secre-
tion from nerve fibers. One might expect 
that SF Glu and Asp would be in full equi-
librium with the plasma, based on size, as 
small physiologic molecules are usually in 
full equilibrium between plasma and syno-
vial fluid [7]. However, the samples from 
the cadavers with no antemortem arthritis 
had significantly decreased EAA SF: 
Plasma concentration ratios compared to 
nine other AA. The significantly greater 
compartmental ratio differences of SF Glu 
and Asp indicate that plasma is not the 
sole or even major source of SF EAA. 
Higher SF: Plasma concentration ratios in 
one cadaver with antemortem arthritis 
and several patients with active inflamma-
tory arthritic processes also support the 
hypothesis that SF EAA concentrations 
reflect local physiologic processes in the 
joint. High AA concentrations obtained in 
several cadaver plasma samples might be 
explained by antemortem systemic inflam-
matory conditions or possibly reflect post-
mortem hemolysis and cytolysis. However, 
EAA compartmental differences reflect arthritis
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tissues, including bone, cartilage and synovium 
[8-10]. Sodium or potassium dependent Glu 
and Asp transport proteins may play role in the 
maintenance of SF EAA concentrations in the 
normal joint. In the CNS, high affinity gluta-
mate/aspartate carrier proteins are capable of 
transporting the neurotransmitters against sev-
eral thousand fold concentration gradients 
using the sodium, potassium electrochemical 
gradient as a driving force, under control condi-
tions [11]. Persistent depolarization of nerves 
reverses the function of the Glu transporter 
pumps, however, resulting in a dumping of 
amino acids [12, 13]. Microdialysis uptake of 
inflammatory perturbations may also induce 
local synovium-based carrier proteins to inap-
propriately allow an increased influx of normally 
excluded substances from the plasma, includ-
ing Glu and Asp. Alternatively, the Glu and Asp 
may require additional mechanisms to migrate 
through the SF, and its accumulation points to 
a failure of normal exclusion physiology during 
joint inflammation. In addition to EAA sources 
from the plasma, SF Glu and Asp concentra-
tions are secondary to local production by resi-
dent cells in the joint capsule [14, 15].
A more likely source may be the stimulated 
release from the primary afferent nerve termi-
nals supplying the joint, as is thought for sub-
stance P release into the joint [16]. Substance 
P has been demonstrated to have SF: Plasma 
ratios of 2-fold in an inflammatory arthropathy 
[17]. The SF EAA values derived from normal rat 
suggest that the low values might be physiolog-
ic in the absence of active arthritis and are 
elevated in inflamed joints [18, 19]. Previous 
studies have demonstrated increased Glu 
immunoreactivity in the median articular nerve 
supplying inflamed joints of monkeys [20]. 
Thus, it is reasonable to assume that gluta-
mate might also be released into the joint by 
nerve fibers. In a k/c induced arthritis model in 
rats, the expected increase in SF Glu was abro-
gated with pretreatment with intra-articular 
lidocaine, which decreases neurotransmitter 
release from peripheral nerves [18]. Local glu-
tamate and aspartate can bind and activate 
peripheral receptors on local osteocytes, chon-
drocytes and synoviocytes to enhance or per-
petuate local inflammation and pathologies 
[15, 19, 21-25]. In a previous study, our group 
demonstrated a correlation between SF EAA 
levels and SF RANTES, MIP1-alpha and IL-8 lev-
els [5]. In the same study, SF WBC counts sig-
nificantly correlated to SF IL-8 levels but not to 
EAA levels.
The disparity of EAA levels between body com-
partments in this study demonstrates a spec-
trum of host pathologic processes and sup-
ports a physiologic relevance of the EAA levels 
and their regulation in the joint. Taken together, 
SF EAA elevations reflect the dynamics of joint 
inflammation and pain. Further studies might 
identify SF EAA concentrations as novel direct 
or surrogate biomarkers that reflect local patho-
logic arthritic processes.
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